Form 4: Revance Therapeutics CEO Mark Foley Increases Stake with $209,400 Stock Purchase

Revance Therapeutics CEO Mark Foley recently purchased 30,000 shares of the company's common stock at $6.98 per share, increasing his direct holdings.

Summary

• On March 6, 2024, Mark J. Foley, the CEO of Revance Therapeutics, Inc., purchased 30,000 shares of common stock at a price of $6.98 per share.
• The total value of the purchase was $209,400.
• Following the transaction, Foley directly owns 1,015,468 shares of Revance Therapeutics common stock.
• Foley also indirectly owns 110,913 shares through the Foley Family Trust.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's significant stock purchase, indicating confidence in the company's prospects. However, it's a single transaction and needs to be considered alongside other factors.

Positives

• The CEO's purchase of a significant number of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive signal, suggesting that a company's leadership believes the stock is undervalued. However, it's important to consider the overall context of the company's performance and industry trends.

Stakeholder Impact

• The CEO's stock purchase could positively influence shareholder sentiment.

Key Dates

Keywords

Revance Therapeutics, RVNC, Mark Foley, Stock Purchase, Beneficial Ownership, SEC Form 4, Insider Trading